

Chronic Conditions Warehouse

Your source for national CMS Medicare and Medicaid research data



Chronic Conditions Warehouse Virtual Research Data Center

CODEBOOK: Medicare Oncology Care Model Files

MAY 2024 | VERSION 1.0

Revision Log

Date	Changed by	Revisions	Version
May 2024	K. Schneider	Initial release of codebook	1.0

Tips on Navigating the Codebook

This document is a detailed codebook that describes each variable in the Medicare Oncology Care Model (OCM) research files. Because the files have many variables, the CCW team has included several ways for users to quickly find the information they need:

- A complete listing of all variables in the files, in alphabetical order based on their SAS variable names
- Individual entries for each variable that contain a short description of the variable, the possible values for the variable, and, in many cases, notes that discuss how the variable was constructed and should be used

The CCW team has included hyperlinks throughout the codebook to make it easier for analysts to navigate between the table of contents and the detailed entries for the individual variables:

- Clicking on any variable name in the Table of Contents takes you to the detailed description for that variable
- From the detailed description for any individual variable, clicking on the [^Back to TOC^](#) link after each variable description takes you back to the Table of Contents

Table of Contents

This section of the codebook contains a list of all variables in alphabetical order based on the SAS variable name.

Quick links: [A](#) [B](#) [C](#) [D](#) [E](#) F G [H](#) [I](#) J K L [M](#) [N](#) [O](#) [P](#) Q [R](#) [S](#) T U V W X Y Z

Variable Details.....	1
AJCC_EDITION	1
BENE_ID	2
CNCR_TYPE_ASGNED.....	3
CNCR_TYPE_RPTD.....	4
CRNT_CLNCL_STUS.....	5
CRNT_CLNCL_STUS_DT.....	6
DOB	7
DOD	8
EPSD_BGN_DT.....	9
EPSD_END_DT	10
ESTROGEN_RECEPTOR.....	11
HER2_AMPLIFICATION.....	12
HISTOLOGY	13
ICD10_CNCR_DGNS_CD_RPTD.....	14
INITL_DGNS_DT.....	15
METASTASIS	16
NODAL_DISEASE.....	18
OCM_PRCTC_ID.....	20
PRFMNC_PRD.....	21
PRMRY_TUMOR.....	22
PROGESTERONE_RECEPTOR	25
RPTD_TO_RGSTRY	26
SEX	27

Variable Details

This section of the codebook contains one entry for each variable in the Medicare Oncology Care Model files. Each entry contains variable details to facilitate understanding and use of the variables.

AJCC_EDITION

LABEL: AJCC Cancer Staging Edition

DESCRIPTION: The edition of the American Joint Committee on Cancer (AJCC) Cancer Staging manual used to describe the patient's cancer stage.

SHORT NAME: AJCC_EDITION

LONG NAME: AJCC_EDITION

TYPE: CHAR

LENGTH: 3

FILE(S): Clinical and staging

SOURCE: Oncology Care Model Data Registry

VALUES: 7th
8th
Null/missing = OCM participant did not report the staging data or it was invalid (reference details in the RPTD_TO_RGSTRY codebook entry)

COMMENT: For any initial diagnosis date (INITL_DGNS_DT) after 1/1/2018, this variable indicates whether the AJCC 7th edition or the AJCC 8th Edition was reported. AJCC 7th Edition is effective for cancer patients diagnosed through 12/31/2017; AJCC 8th Edition is effective for cancer patients diagnosed on or after 1/1/2018. To support participants that did not have AJCC 8th Edition staging available, the OCM Data Registry accepted either AJCC 7th Edition or AJCC 8th Edition staging values for cancer patients diagnosed on or after 1/1/2018.

[^ Back to TOC ^](#)

BENE_ID

LABEL: Encrypted CCW Beneficiary ID

DESCRIPTION: The unique CCW identifier for a beneficiary.

The CCW assigns a unique beneficiary identification number to each individual who receives Medicare and/or Medicaid and uses that number to identify an individual's records in all CCW data files (e.g., Medicare claims and enrollment, T-MSIS claims, and MDS assessment data).

This number does not change during a beneficiary's lifetime, and CCW uses each number only once.

The BENE_ID is specific to the CCW and is not applicable to any other identification system or data source.

SHORT NAME: BENE_ID

LONG NAME: BENE_ID

TYPE: CHAR

LENGTH: 15

FILE(S): Clinical and staging
Current clinical status

SOURCE: CCW

VALUES: —

COMMENT: —

[^ Back to TOC ^](#)

CNCR_TYPE_ASGNED

LABEL:	OCM-Assigned Cancer Type
DESCRIPTION:	OCM-assigned cancer type.
SHORT NAME:	CNCR_TYPE_ASGNED
LONG NAME:	CNCR_TYPE_ASGNED
TYPE:	CHAR
LENGTH:	35
FILE(S):	Clinical and staging
SOURCE:	CMS Oncology Care Model data
VALUES:	Acute Leukemia Anal Cancer Bladder Cancer Breast Cancer CNS Tumor Chronic Leukemia Endocrine Tumor Female GU Cancer other than Ovary Gastro/Esophageal Cancer Head and Neck Cancer Kidney Cancer Liver Cancer Lung Cancer Lymphoma MDS Malignant Melanoma Multiple Myeloma Ovarian Cancer Pancreatic Cancer Prostate Cancer Small Intestine/Colorectal Cancer
COMMENT:	OCM classified each episode by cancer type (e.g., prostate, lymphoma, breast). Cancer type was defined using the plurality of cancer diagnoses on qualifying evaluation and management (E&M) provider visits in the carrier file that occurred during the episode. The cancer type is used in categorizing episodes for reporting, monitoring, and risk adjustment purposes.

[^ Back to TOC ^](#)

CNCR_TYPE_RPTD

LABEL: Participant-Reported Cancer Type

DESCRIPTION: Participant-reported cancer type.

SHORT NAME: CNCR_TYPE_RPTD

LONG NAME: CNCR_TYPE_RPTD

TYPE: CHAR

LENGTH: 35

FILE(S): Clinical and staging

SOURCE: Oncology Care Model Data Registry

VALUES: Acute Leukemia
Anal Cancer
Bladder Cancer
Breast Cancer
CNS Tumor
Chronic Leukemia
Endocrine Tumor
Female GU Cancer other than Ovary
Gastro/Esophageal Cancer
Head and Neck Cancer
Kidney Cancer
Liver Cancer
Lung Cancer
Lymphoma
MDS
Malignant Melanoma
Multiple Myeloma
Ovarian Cancer
Pancreatic Cancer
Prostate Cancer
Small Intestine/Colorectal Cancer
Null/missing = cancer type was not reported by OCM participant, or it was invalid (reference details in the RPTD_TO_RGSTRY codebook entry)

COMMENT: —

[^ Back to TOC ^](#)

CRNT_CLNCL_STUS

LABEL: Current Clinical Status

DESCRIPTION: Current clinical status.

SHORT NAME: CRNT_CLNCL_STUS

LONG NAME: CRNT_CLNCL_STUS

TYPE: CHAR

LENGTH: 45

FILE(S): Current clinical status

SOURCE: Oncology Care Model Data Registry

VALUES:

Value	Description
Deceased	Patient is deceased
Initial diagnosis	Treatment of the disease has started, and the disease has not been re-evaluated since treatment began
Local or regional recurrence/Relapse	Recurrence is the local or regional return of a solid tumor cancer after a clinically disease-free interval. Relapse is the return of a leukemia, lymphoma, or other hematopoietic malignancy that was not previously clinically apparent or symptomatic
Metastasis	Evidence of cancer in a site other than the primary tumor site that was not present at initial diagnosis or initial relapse
No evidence of disease/Remission	When radiological examinations or complete surgical resection of tumor with negative margins show no evidence of cancer in a patient who is being or has been treated for cancer (including a previous recurrence/relapse); or there is no morphological evidence of leukemia
Progressive disease	Cancer continues to grow or spread since initial diagnosis.
Recurrent or progressive disease	Defined as "Local or Regional Recurrence/Relapse" or "Progressive Disease" as above. This status was only available to report prior to July 1, 2017, and will only appear for patients whose episodes had not yet begun
Responding	Cancer is decreasing in extent or severity in response to treatment
Stable disease	Cancer is neither decreasing nor increasing in extent or severity
Stable, Responding, or No Evidence of Disease	Defined as "Stable Disease," "Responding," or "No Evidence of Disease/Remission" as above. This status was only available to report prior to July 1, 2017, and will only appear for patients whose episodes had not yet begun.

COMMENT: Participants were required to enter current clinical status at least one time during each 6-month episode, and were expected to update the current clinical status if changes occurred. When there was documentation to support a current clinical status value of "Metastasis" during the episode, practices were instructed to prioritize reporting this value over other current clinical statuses that were documented during the episode, if they only going to report one status during the episode. Current clinical status may not have been reported for every episode.

[^ Back to TOC ^](#)

CRNT_CLNCL_STUS_DT

LABEL: Current Clinical Status Date

DESCRIPTION: The date the current clinical status (variable called CRNT_CLNCL_STUS) was reported.

SHORT NAME: CRNT_CLNCL_STUS_DT

LONG NAME: CRNT_CLNCL_STUS_DT

TYPE: DATE

LENGTH: 8

FILE(S): Current Clinical Status

SOURCE: Oncology Care Model Data Registry

VALUES: Ex — 08/22/2019

COMMENT: Formatted as MMDDYY10 in SAS.

Current clinical status may not have been entered for every episode. Current clinical status date is not available for episodes occurring in performance period 3 (PRFMNC_PRD =3).

[^ Back to TOC ^](#)

DOB

LABEL:	Beneficiary Date of Birth
DESCRIPTION:	Beneficiary date of birth.
SHORT NAME:	DOB
LONG NAME:	DOB
TYPE:	DATE
LENGTH:	8
FILE(S):	Clinical and staging
SOURCE:	CCW Master Beneficiary Summary File (MBSF)
VALUES:	Ex — 10/12/1945
COMMENT:	The CMS Oncology Care Model team obtained this information from the MBSF. Formatted as MMDDYY10 in SAS

[^ Back to TOC ^](#)

DOD

LABEL: Beneficiary Date of Death

DESCRIPTION: Beneficiary date of death.

SHORT NAME: DOD

LONG NAME: DOD

TYPE: DATE

LENGTH: 8

FILE(S): Clinical and staging

SOURCE: CCW Master Beneficiary Summary File (MBSF)

VALUES: Ex — 10/12/2020

COMMENT: The CMS Oncology Care Model team obtained this information from the MBSF.
Formatted as MMDDYY10 in SAS

[^ Back to TOC ^](#)

EPSD_BGN_DT

LABEL:	Episode Beginning Date
DESCRIPTION:	Episode beginning date.
SHORT NAME:	EPSD_BGN_DT
LONG NAME:	EPSD_BGN_DT
TYPE:	DATE
LENGTH:	8
FILE(S):	Clinical and staging
SOURCE:	CMS Oncology Care Model data
VALUES:	Ex — 10/12/2018
COMMENT:	Formatted as MMDDYY10 in SAS

In OCM, episodes were initiated on the date of service for an initial Part B chemotherapy drug claim with a corresponding cancer diagnosis on the claim, or on the fill date for an initial Part D chemotherapy drug claim with a corresponding Part B claim for cancer on the date of, or in the 59 days preceding, the drug claim. Episodes continued for six months after the triggering chemotherapy event, as long as the beneficiary met eligibility requirements for all six months; the ending date of the episode is the variable EPSD_END_DT. Beneficiaries who continued to receive chemotherapy after completing the six-month episode initiated a new episode.

[^ Back to TOC ^](#)

EPSD_END_DT

LABEL:	Episode Ending Date
DESCRIPTION:	Episode ending date.
SHORT NAME:	EPSD_END_DT
LONG NAME:	EPSD_END_DT
TYPE:	DATE
LENGTH:	8
FILE(S):	Clinical and staging
SOURCE:	CMS Oncology Care Model data
VALUES:	Ex — 04/12/2019
COMMENT:	Formatted as MMDDYY10 in SAS

In OCM, episodes were initiated on the date of service for an initial Part B chemotherapy drug claim with a corresponding cancer diagnosis on the claim, or on the fill date for an initial Part D chemotherapy drug claim with a corresponding Part B claim for cancer on the date of, or in the 59 days preceding, the drug claim (variable called EPSD_BGN_DT). Episodes continued for six months after the triggering chemotherapy event, as long as the beneficiary met eligibility requirements for all six months; the ending date of the episode is this variable (EPSD_END_DT). Beneficiaries who continued to receive chemotherapy after completing the six-month episode initiated a new episode.

[^ Back to TOC ^](#)

ESTROGEN_RECEPTOR

LABEL:	Breast Cancer Estrogen Receptor
DESCRIPTION:	Breast cancer estrogen receptor.
SHORT NAME:	ESTROGEN_RECEPTOR
LONG NAME:	ESTROGEN_RECEPTOR
TYPE:	CHAR
LENGTH:	30
FILE(S):	Clinical and staging
SOURCE:	Oncology Care Model Data Registry
VALUES:	None Selected Not Tested Negative Positive Null/missing = n/a (not breast cancer); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)
COMMENT:	Practices were required to report clinical and staging data associated with each beneficiary's assigned cancer. Estrogen Receptor (ER) is routinely tested for breast cancer and is necessary for staging and treatment decisions. This variable is only populated for episodes with breast cancer.

[^ Back to TOC ^](#)

HER2_AMPLIFICATION

LABEL:	HER2 Amplification
DESCRIPTION:	HER2 amplification.
SHORT NAME:	HER2_AMPLIFICATION
LONG NAME:	HER2_AMPLIFICATION
TYPE:	CHAR
LENGTH:	30
FILE(S):	Clinical and staging
SOURCE:	Oncology Care Model Data Registry
VALUES:	None Selected Not Tested Equivocal Negative Positive Null/missing = n/a (not breast gastro/esophageal cancer); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)
COMMENT:	Practices were required to report clinical and staging data associated with each beneficiary's assigned cancer. HER2 Amplification is routinely tested for breast cancer and gastro/esophageal cancer. It is necessary for breast cancer staging and helps determine treatment decisions. This variable is only populated for episodes with breast cancer or gastro/esophageal cancer.

[^ Back to TOC ^](#)

HISTOLOGY

LABEL:	Histology
DESCRIPTION:	Histology.
SHORT NAME:	HISTOLOGY
LONG NAME:	HISTOLOGY
TYPE:	CHAR
LENGTH:	30
FILE(S):	Clinical and staging
SOURCE:	Oncology Care Model Data Registry
VALUES:	Adenocarcinoma Adenocarcinoma, NOS Carcinoma, NOS Inflammatory NSCLC - Adenocarcinoma NSCLC - Large Cell NSCLC - Squamous Cell Non-small cell carcinoma None Selected Other Small Cell Lung Cancer Small cell carcinoma, NOS Squamous cell carcinoma Squamous cell carcinoma, NOS Null/missing = n/a (not applicable for the type of cancer reported); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)
COMMENT:	Practices were required to report clinical and staging data associated with each beneficiary's assigned cancer. This variable is only populated for episodes with breast cancer, some types of gastro/esophageal cancer (ICD10 diagnosis codes C15.3, C15.4, C15.5, C15.8, C15.9, C16.0), and some types of lung cancer (ICD10 diagnosis codes C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C39.0, and C39.9).

[^ Back to TOC ^](#)

ICD10_CNCR_DGNS_CD_RPTD

LABEL:	ICD10 Cancer Diagnosis Code Reported by Participant
DESCRIPTION:	ICD10 cancer diagnosis code reported by participant. The diagnosis code for the cancer type is classified using the International Classification of Diseases, 10 th Revision, clinical modification (ICD-10-CM).
SHORT NAME:	ICD10_CNCR_DGNS_CD_RPTD
LONG NAME:	ICD10_CNCR_DGNS_CD_RPTD
TYPE:	CHAR
LENGTH:	7
FILE(S):	Clinical and Staging Current Clinical Status
SOURCE:	Oncology Care Model Data Registry
VALUES:	3- to 7-digit alphanumeric value (without decimals) Ex — C50211
COMMENT:	Practices were required to report clinical and staging data associated with each beneficiary's assigned cancer.

[^ Back to TOC ^](#)

INITL_DGNS_DT

LABEL: Initial Diagnosis Date

DESCRIPTION: Initial diagnosis date.

SHORT NAME: INITL_DGNS_DT

LONG NAME: INITL_DGNS_DT

TYPE: DATE

LENGTH: 8

FILE(S): Clinical and staging
Current clinical status

SOURCE: Oncology Care Model Data Registry

VALUES: Ex — 03/29/2015

COMMENT: Formatted as MMDDYY10 in SAS

[^ Back to TOC ^](#)

METASTASIS

LABEL: Metastasis Staging

DESCRIPTION: Metastasis staging.

SHORT NAME: METASTASIS

LONG NAME: METASTASIS

TYPE: CHAR

LENGTH: 30

FILE(S): Clinical and staging

SOURCE: Oncology Care Model Data Registry

VALUES: None Selected,
M0,
M1,
M1a,
M1a(0),
M1a(1),
M1b,
M1b(0),
M1b(1),
M1c,
M1c(0),
M1c(1),
M1d,
M1d(0),
M1d(1),
cM0(i+),
pM1,
pM1a,
pM1b,
pM1c
Null/missing = n/a (not required for cancer type); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)

COMMENT: Practices were required to report clinical and staging data associated with each beneficiary's assigned cancer. The Metastasis (M) category describes the presence of distant metastasis in sites and/or organs outside the local tumor area and regional nodes as defined by cancer site.

Metastasis reporting was required for breast cancer, female GU other than ovarian cancer, gastro-esophageal cancer, kidney cancer, malignant melanoma, ovarian cancer, pancreatic cancer, and prostate cancer, and for the following cancer types for specific diagnosis codes:

- Anal cancer — all diagnoses (except for C21.2 under the AJCC 8th edition)

- Bladder cancer — C65.1, C65.2, C65.9, C66.1, C66.2, C66.9, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, and C68.0
- Endocrine tumors — C73, C74.00, C74.01, C74.02, C74.10, C74.11, C74.12, C74.90, C74.91, C74.92, C7A.010, C7A.011, C7A.012, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.026, C7A.029, C7A.090, C7A.091 (AJCC 8th edition only), C7A.092, C7A.1, and C7A.8
- Head and neck cancer — AJCC 8th edition: all diagnoses EXCEPT C30.1, C33, C69.10, C69.11, C69.12, C69.80, C69.81, C69.82, C69.90, C69.91, and C69.92. AJCC 7th edition: all diagnoses EXCEPT C14.0, C14.2, C14.8, C30.1, C31.8, C31.9, C32.3, C33, C69.10, C69.11, C69.12, C69.90, C69.91, C69.92, and C76.0
- Liver cancer — C22.0, C22.1, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, C23, C24.0, and C24.1
- Lung cancer — C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C45.0, C45.7, and C45.9
- Lymphoma — AJCC 8th edition only: C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, C84.A0, C84.A1, C84.A2, C84.A3, C84.A4, C84.A5, C84.A6, C84.A7, C84.A8, C84.A9, C86.3, and C86.6
- Small intestine/colorectal cancer — C17.0, C17.1, C17.2, C17.8, C17.9, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, and C20

[^ Back to TOC ^](#)

NODAL_DISEASE

LABEL: Nodal Disease Staging

DESCRIPTION: Nodal disease staging.

SHORT NAME: NODAL_DISEASE

LONG NAME: NODAL_DISEASE

TYPE: CHAR

LENGTH: 30

FILE(S): Clinical and staging

SOURCE: Oncology Care Model Data Registry

VALUES: None Selected,
N0,
N0(i+),
N0a,
N0b,
N1,
N1a,
N1b,
N1c,
N1mi,
N2,
N2a,
N2b,
N2c,
N2mi,
N3,
N3a,
N3b,
N3c,
NX,
pN0,
pN0(i+),
pN0(i-),
pN0(mol+),
pN0(mol-),
pN1,
pN1a,
pN1b,
pN1c,
pN1mi,
pN2,
pN2a,

pN2b,
pN2c,
pN3,
pN3a,
pN3b,
pN3c,
pNX

Null/missing = n/a (not required for cancer type); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)

COMMENT: Practices were required to report clinical and staging data associated with each beneficiary’s assigned cancer. Nodal Disease (N) category describes the regional lymph node involvement as defined for each cancer site. It may include the absence or presence of cancer in regional nodes and/or the number of positive nodes, size, or involvement.

Nodal disease reporting was required for breast cancer, female GU other than ovarian cancer, gastro-esophageal cancer, kidney cancer, malignant melanoma, ovarian cancer, pancreatic cancer, and prostate cancer, and for the following cancer types for specific diagnosis codes:

- Anal cancer – all diagnoses (except for C21.2 under the AJCC 8th edition)
- Bladder cancer – C65.1, C65.2, C65.9, C66.1, C66.2, C66.9, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, and C68.0
- Endocrine tumors – C73, C74.00, C74.01, C74.02, C74.10, C74.11, C74.12, C74.90, C74.91, C74.92, C7A.010, C7A.011, C7A.012, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.026, C7A.029, C7A.090, C7A.091 (AJCC 8th edition only), C7A.092, C7A.1, and C7A.8
- Head and neck cancer – AJCC 8th edition: all diagnoses EXCEPT C30.1, C33, C69.10, C69.11, C69.12, C69.80, C69.81, C69.82, C69.90, C69.91, and C69.92. AJCC 7th edition: all diagnoses EXCEPT C14.0, C14.2, C14.8, C30.1, C31.8, C31.9, C32.3, C33, C69.10, C69.11, C69.12, C69.90, C69.91, C69.92, and C76.0
- Liver cancer – C22.0, C22.1, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, C23, C24.0, and C24.1
- Lung cancer – C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C45.0, C45.7, and C45.9
- Lymphoma – AJCC 8th edition only: C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, C84.A0, C84.A1, C84.A2, C84.A3, C84.A4, C84.A5, C84.A6, C84.A7, C84.A8, C84.A9, C86.3, and C86.6
- Small intestine/colorectal cancer – C17.0, C17.1, C17.2, C17.8, C17.9, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, and C20

[^ Back to TOC ^](#)

OCM_PRCTC_ID

LABEL: OCM-Assigned Practice ID
DESCRIPTION: OCM-assigned practice ID
SHORT NAME: OCM_PRCTC_ID
LONG NAME: OCM_PRCTC_ID
TYPE: CHAR
LENGTH: 7
FILE(S): Clinical and staging
SOURCE: CMS Oncology Care Model data
VALUES: Ex — OCM-123
COMMENT: Formatted as OCM-###

[^ Back to TOC ^](#)

PRFMNC_PRD

LABEL:	OCM 6 Month Performance Period
DESCRIPTION:	OCM six-month performance period. Episodes of care were organized by performance periods, which are the six-month periods of time during which a cohort of episodes terminated and was reconciled together.
SHORT NAME:	PRFMNC_PRD
LONG NAME:	PRFMNC_PRD
TYPE:	NUM
LENGTH:	3
FILE(S):	Clinical and staging
SOURCE:	Oncology Care Model Data Registry
VALUES:	3 = Episodes beginning July 2, 2017–January 1, 2018 4 = Episodes beginning January 2, 2018–July 1, 2018 5 = Episodes beginning July 2, 2018–January 1, 2019 6 = Episodes beginning January 2, 2019–July 1, 2019 7 = Episodes beginning July 2, 2019–January 1, 2020 8 = Episodes beginning January 2, 2020–July 1, 2020 9 = Episodes beginning July 2, 2020–January 1, 2021 10 = Episodes beginning January 2, 2021–July 1, 2021 11 = Episodes beginning July 2, 2021–December 31, 2021
COMMENT:	In OCM, episodes are initiated on the date of service for an initial Part B chemotherapy drug claim with a corresponding cancer diagnosis on the claim, or on the fill date for an initial Part D chemotherapy drug claim with a corresponding Part B claim for cancer on the date of, or in the 59 days preceding, the drug claim. Episodes continued for six months after the triggering chemotherapy event, as long as the beneficiary met eligibility requirements for all six months. Beneficiaries who continued to receive chemotherapy after completing the six-month episode initiated a new episode. Data reported for the first two OCM performance periods have not been shared because obstacles were encountered that made the data reported questionable in accuracy and reliability.

[^ Back to TOC ^](#)

PRMRY_TUMOR

LABEL: Primary Tumor Staging

DESCRIPTION: Primary tumor staging.

SHORT NAME: PRMRY_TUMOR

LONG NAME: PRMRY_TUMOR

TYPE: CHAR

LENGTH: 30

FILE(S): Clinical and staging

SOURCE: Oncology Care Model Data Registry

VALUES: Multiple Primaries,
None Selected,
T0,
T1,
T1a,
T1a1,
T1a2,
T1b,
T1b1,
T1b2,
T1c,
T1c1,
T1c2,
T1c3,
T1d,
T1mi,
T2,
T2a,
T2a1,
T2a2,
T2b,
T2c,
T3,
T3a,
T3b,
T3c,
T3d,
T4,
T4a,
T4b,
T4c,
T4d,

TX,
Ta,
Tis,
Tis (DCIS),
Tis (LCIS),
Tis (Paget's),
Tis (Paget),
pT0,
pT1,
pT1a,
pT1b,
pT1c,
pT1mi,
pT2,
pT2a,
pT2b,
pT2c,
pT3,
pT3a,
pT3b,
pT4,
pT4a,
pT4b,
pT4c,
pT4d,
pTX,
pTa,
pTis,
pTis (DCIS),
pTis (LCIS),
pTis (Paget's),
pTis (Paget)

Null/missing = n/a (not required for cancer type); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)

COMMENT: Practices were required to report clinical and staging data associated with each beneficiary's assigned cancer. Primary Tumor (T) describes the size and/or the extension of the primary tumor specifically defined for each cancer site. Generally, the higher the Primary Tumor category (value), the greater the extent of the disease and generally the worse the prognosis; some exceptions exist.

Primary tumor reporting was required for breast cancer, female GU other than ovarian cancer, gastro-esophageal cancer, kidney cancer, malignant melanoma, ovarian cancer, pancreatic cancer, and prostate cancer, and for the following cancer types for specific diagnosis codes:

- Anal cancer – all diagnoses (except for C21.2 under the AJCC 8th edition)
- Bladder cancer – C65.1, C65.2, C65.9, C66.1, C66.2, C66.9, C67.0, C67.1, C67.2, C67.3, C67.4, C67.5, C67.6, C67.7, C67.8, C67.9, and C68.0

- Endocrine tumors – C73, C74.00, C74.01, C74.02, C74.10, C74.11, C74.12, C74.90, C74.91, C74.92, C7A.010, C7A.011, C7A.012, C7A.020, C7A.021, C7A.022, C7A.023, C7A.024, C7A.025, C7A.026, C7A.029, C7A.090, C7A.091 (AJCC 8th edition only), C7A.092, C7A.1, and C7A.8
- Head and neck cancer – AJCC 8th edition: all diagnoses EXCEPT C30.1, C33, C69.10, C69.11, C69.12, C69.80, C69.81, C69.82, C69.90, C69.91, and C69.92. AJCC 7th edition: all diagnoses EXCEPT C14.0, C14.2, C14.8, C30.1, C31.8, C31.9, C32.3, C33, C69.10, C69.11, C69.12, C69.90, C69.91, C69.92, and C76.0
- Liver cancer – C22.0, C22.1, C22.2, C22.3, C22.4, C22.7, C22.8, C22.9, C23, C24.0, and C24.1
- Lung cancer – C34.00, C34.01, C34.02, C34.10, C34.11, C34.12, C34.2, C34.30, C34.31, C34.32, C34.80, C34.81, C34.82, C34.90, C34.91, C34.92, C45.0, C45.7, and C45.9
- Lymphoma – AJCC 8th edition only: C84.00, C84.01, C84.02, C84.03, C84.04, C84.05, C84.06, C84.07, C84.08, C84.09, C84.10, C84.11, C84.12, C84.13, C84.14, C84.15, C84.16, C84.17, C84.18, C84.19, C84.A0, C84.A1, C84.A2, C84.A3, C84.A4, C84.A5, C84.A6, C84.A7, C84.A8, C84.A9, C86.3, and C86.6
- Small intestine/Colorectal cancer – C17.0, C17.1, C17.2, C17.8, C17.9, C18.0, C18.1, C18.2, C18.3, C18.4, C18.5, C18.6, C18.7, C18.8, C18.9, C19, and C20

[^ Back to TOC ^](#)

PROGESTERONE_RECEPTOR

LABEL: Breast Cancer Progesterone Receptor

DESCRIPTION: Breast cancer progesterone receptor.

SHORT NAME: PROGESTERONE_RECEPTOR

LONG NAME: PROGESTERONE_RECEPTOR

TYPE: CHAR

LENGTH: 30

FILE(S): Clinical and staging

SOURCE: Oncology Care Model Data Registry

VALUES: None Selected
Not Tested
Negative
Positive
Null/missing = n/a (not breast cancer); or not reported by OCM participant (reference details in the RPTD_TO_RGSTRY codebook entry)

COMMENT: Practices were required to report clinical and staging data associated with each beneficiary's assigned cancer. Progesterone Receptor (PR) is routinely tested for breast cancer and is necessary for staging and treatment decisions. This variable is only populated for episodes with breast cancer.

[^ Back to TOC ^](#)

RPTD_TO_RGSTRY

LABEL:	Participant Reported Episode to OCM Registry
DESCRIPTION:	Indicates whether the OCM participant reported data on this episode to the OCM registry.
SHORT NAME:	RPTD_TO_RGSTRY
LONG NAME:	RPTD_TO_RGSTRY
TYPE:	NUM
LENGTH:	3
FILE(S):	Clinical and staging
SOURCE:	Oncology Care Model Data Registry
VALUES:	0 = No 1 = Yes
COMMENT:	OCM participants submitted staging and clinical data to the OCM Data Registry (OCMR), a web-based data submission and collection tool, for episodes that were attributed to their practice.

Beneficiaries not reported to the OCMR (RPTD_TO_RGSTRY=0) have blank values for the following variables in the Clinical and Staging file: AJCC_EDITION, CNCR_TYPE_RPTD, ESTROGEN_RECEPTOR, HER2_AMPLIFICATION, HISTOLOGY, ICD10_CNCR_DGNS_CD_RPTD, INITL_DGNS_DT, METASTASIS, NODAL_DISEASE, PRMRY_TUMOR, and PROGESTERONE_RECEPTOR. Such beneficiaries will also not have records in the current clinical status file.

A second group of beneficiaries also has blank values for the variables listed above, those where RPTD_TO_RGSTRY = 1 but whose reported values were determined to be invalid for one of the following reasons:

1. Participant-reported cancer type (CNCR_TYPE_RPTD) not equal to OCM-assigned cancer type (CNCR_TYPE_ASGNED)
2. Practice reporting the data was not the same as the practice to which the beneficiary's episode was attributed
3. Not all information was completely reported, or,
4. Multiple records with conflicting values for the primary tumor, nodal disease, and/or metastasis elements were reported (and it was not known which were correct).

In the first five performance periods, if a practice did not report to the OCMR, they were ineligible to be considered for a performance-based payment (reporting was required for at least 75% of episodes). For the 6th through 11th performance periods, practices were permitted to opt out of reporting due to external burdens associated with the COVID19 PHE, and were still eligible to receive performance-based payments.

[^ Back to TOC ^](#)

SEX

LABEL:	Beneficiary Sex
DESCRIPTION:	Beneficiary sex.
SHORT NAME:	SEX
LONG NAME:	SEX
TYPE:	NUM
LENGTH:	3
FILE(S):	Clinical and staging
SOURCE:	CCW Master Beneficiary Summary File (MBSF)
VALUES:	1 = Male 2 = Female
COMMENT:	The CMS Oncology Care Model team obtained this information from the MBSF.

[^ Back to TOC ^](#)